UNLABELLED We studied the changing patterns of radiopharmaceutical use and the incidence of adverse events (AEs) to PET radiopharmaceuticals, non-PET radiopharmaceuticals, and adjunctive nonradioactive pharmaceuticals in nuclear medicine from 2007 to 2011. METHODS Fifteen academic institutions submitted quarterly reports of radiopharmaceutical use and AEs covering 2007-2011. RESULTS 1,024,1...

introduction: biodistribution study in animal models bearing tumors is one of the most important procedures in evaluation of fractional uptake of radiopharmaceuticals in the tumor and non-tumor organs. the aim of this study was to develop a new software-based method to determine activities that accumulate in the main organs as well as the tumor based on scintigraphy images, thereby obviating th...

Positron Emission Tomography (PET) experienced accelerated development and has become an established method for medical research and clinical routine diagnostics on patient individualized basis. Development and availability of new radiopharmaceuticals specific for particular diseases is one of the driving forces of the expansion of clinical PET. The future development of the ⁶⁸Ga-radiopharmaceu...

UNLABELLED Universally applied standards for administering radiopharmaceutical doses in children do not presently exist. Hence, pediatric radiopharmaceutical dosimetry varies considerably from institution to institution and is generally based on the recommended adult dose adjusted for body mass. METHODS We surveyed 13 pediatric hospitals in North America to obtain objective data on dosimetry ...

BACKGROUND South African nuclear medicine imaging departments have been fortunate in being able to receive an uninterrupted supply of molybdenum-99 (99Mo)/technetium-99m (99mTc) generators. Nuclear medicine radiographers practising in private sector services in the northern Gauteng region indicated a possible problem with the quantities of wasted and unused 99mTc radiopharmaceuticals returned t...

objective(s):in this study, 166ho-1,2-propylene di-amino tetra(methy1enephosphonicacid) (166ho-pdtmp) complex  was prepared as a bone palliation agent. materials and methods:the complex was successfully prepared using an in-house synthesized edtmp ligand and 166hocl3. ho-166 chloride was obtained by thermal neutron irradiation (1 × 1013 n.cm-2.s-1) of natural ho(no3)3 samples  followed by radio...